Earnings ·
Reports Q3 net loss of $3.5M on $2.4M R&D as cash falls to $8.5M
INTSIntensity Therapeutics, Inc.
Intensity Therapeutics reported a third-quarter 2026 net loss of $3.5 million, or $1.09 per share, compared to a $2.7 million loss in the prior-year period. Research and development expenses rose to $2.4 million from $1.6 million due to resumed patient enrollment in the Phase 3 INVINCIBLE-3 sarcoma trial and new manufacturing batches. General and administrative expenses remained flat at $1.2 million. The company ended the quarter with $8.5 million in cash and cash equivalents, down from $11.9 million at year-end 2025, after raising net proceeds of $1.5 million through its at-the-market equity facility. Intensity Therapeutics is a late-stage clinical biotechnology company focused on developing novel intratumoral cancer therapies.